Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Novartis (Details)

v3.23.1
Licensing and Other Arrangements - Novartis (Details)
$ / shares in Units, $ in Thousands, € in Millions
 3 Months Ended
Aug. 24, 2017
USD ($)
item
agreement
$ / shares
shares
Aug. 24, 2017
EUR (€)
item
agreement
shares
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Jan. 03, 2023
$ / shares
Dec. 31, 2022
USD ($)
Licensing and other arrangements            
Stock price (in dollars per share) | $ / shares         $ 18.66  
Revenue from contracts with customers       $ 2,750    
Novartis Pharma AG | Gevokizumab License Agreement and IL-1 Target License Agreement            
Licensing and other arrangements            
Transaction price $ 40,200          
Cash payment received 25,700          
License agreement consideration received, repayment of debt 14,300          
Common stock premium $ 200          
Number of license agreements | agreement 2 2        
Number of arrangements | item 1 1        
Number of performance obligations | item 2 2        
Remaining performance obligations     $ 0      
Revenue from contracts with customers     0 $ 0    
Contract assets     0     $ 0
Contract liabilities     0     0
Capitalized contract costs     $ 0     $ 0
Novartis Pharma AG | Gevokizumab License Agreement            
Licensing and other arrangements            
License agreement consideration received $ 30,000          
Cash payment received 15,700          
License agreement consideration received, repayment of debt 14,300 € 12.0        
Proceeds from issuance of common stock 5,000          
Common stock premium 200          
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 438,000          
Agreement termination prior written notice period 6 months 6 months        
Novartis Pharma AG | Gevokizumab License Agreement | Common Stock            
Licensing and other arrangements            
Shares issued (in shares) | shares 539,131 539,131        
Purchase price (in dollars per share) | $ / shares $ 9.2742          
Issuance of common stock, fair value $ 4,800          
Stock price (in dollars per share) | $ / shares $ 8.93          
Novartis Pharma AG | IL-1 Target License Agreement            
Licensing and other arrangements            
Cash payment received $ 10,000